GSK:NYSE
GSK plc
$ 51.45
arrow_upward
+0.39%(+0.20) 1D
$ 51.45
0.00% (0.00)
bedtimeAfter hours
Closed: 7-р сарын 15, 16:00:03 (GMT-4) · USD
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for GSK...
Open
$ 51.22
High
$ 51.82
Low
$ 51.08
Mkt. cap
104.09Т
Avg. vol.
3.79 сая
Volume
2.80 сая
Dividend
3.49%
Quarterly dividend
$ 0.45
Ex-dividend date
2026 оны 5-р сарын 14
P/E ratio
13.49
52-wk high
$ 61.70
52-wk low
$ 35.45
EPS
$ 3.81
Beta
0.27
Shares outstanding
2.02 тэрбум
No. of employees
67 мян
Open
$ 51.22
High
$ 51.82
Low
$ 51.08
Mkt. cap
104.09Т
Avg. vol.
3.79 сая
Volume
2.80 сая
Dividend
3.49%
Quarterly dividend
$ 0.45
Ex-dividend date
2026 оны 5-р сарын 14
P/E ratio
13.49
52-wk high
$ 61.70
52-wk low
$ 35.45
EPS
$ 3.81
Beta
0.27
Shares outstanding
2.02 тэрбум
No. of employees
67 мян
News stories
From sources across the web
Stock Titan
·
2 цагийн өмнө
Nuvalent, Inc. (NUVL) director exits holdings in $124 GSK merger
marketscreener.com
·
6 цагийн өмнө
GlaxoSmithKline LLC completed the acquisition of Nuvalent, Inc. from Deerfield Management Company, L.P. and others.
TipRanks
·
8 цагийн өмнө
GSK’s New Phase 3 Ovarian Cancer Trial Puts Mo-Rez in the First-Line Spotlight
London South East
·
11 цагийн өмнө
IN BRIEF: GSK completes USD10.6 billion acquisition of Nuvalent
Profile
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
About GSK plc
CEOEmma Walmsley | Emma Walmsley
Employees66.8 мян
Founded2000 оны 12-р сарын 27
Headquarters-
SectorPharmaceutical industry
Websitegsk.com
AI content may include mistakes. Learn more